GLP-1 Coverage Guide is a private website. We are not Medicare, the Centers for Medicare & Medicaid Services (CMS), or any government agency, and we are not affiliated with or endorsed by them.
Text size:

Wegovy under the Medicare GLP-1 Bridge

Short answer: Wegovy — Novo Nordisk's weekly semaglutide injection for weight management — is one of the three medications covered at a flat $50/month under the Medicare GLP-1 Bridge. With an approved prior authorization, you fill it at a participating pharmacy like any monthly prescription.

Program facts last verified against CMS: July 21, 2026

What Wegovy is

Wegovy is a once-weekly self-injection of semaglutide, a GLP-1 receptor agonist that reduces appetite and slows stomach emptying. In its pivotal trials, average weight loss ran around 15% of body weight over about 68 weeks alongside diet and activity changes. It also carries an FDA-approved indication for reducing cardiovascular risk in people with heart disease and overweight — relevant to many Tier 3 qualifiers with a prior heart attack or stroke.

Common early side effects are gastrointestinal — nausea, constipation, diarrhea — typically strongest during dose increases and improving with time. The dose escalates gradually over several months from a low starting dose to the maintenance dose, which is designed to manage exactly those effects.

Getting it at $50

Under the Bridge there's no formulary tier or plan-by-plan variation to research: if your prior authorization is approved, Wegovy is $50 per monthly fill, nationwide. Which of the three covered products fits you best is a clinical conversation — cardiovascular history, tolerability, and your prescriber's judgment all factor in. If supply of one product tightens, switching within the program is possible with an updated authorization.

Take the 2-minute eligibility check →

Common questions

Is Wegovy the same as Ozempic?

Same molecule (semaglutide), different products: Ozempic is approved and dosed for type 2 diabetes; Wegovy for weight management and cardiovascular risk reduction. The Bridge covers Wegovy; Ozempic runs through standard Part D for diabetes.

How much weight do people lose on Wegovy?

Trial averages were around 15% of body weight over roughly 16 months — individual results vary widely, and Medicare-age results depend on many factors your prescriber can discuss.

Do I inject it myself?

Yes — a once-weekly injection with a prefilled pen, any day of the week, with simple training from your pharmacist or prescriber's office.

Related

Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF